BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8702313)

  • 1. [Molecular analysis of the estrogen receptor (ER) gene in association with ER negativity in breast cancer].
    Iwase H; Kobayashi S; Iwata H; Yamashita T; Ito K; Toyama T; Hara Y; Greenman J; Mathew CG
    Gan To Kagaku Ryoho; 1996 Mar; 23 Suppl 1():61-5. PubMed ID: 8702313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women.
    Noma C; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
    Cancer Lett; 2004 Jul; 210(2):197-203. PubMed ID: 15183535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood.
    Yaich L; Dupont WD; Cavener DR; Parl FF
    Cancer Res; 1992 Jan; 52(1):77-83. PubMed ID: 1345763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
    Kim HJ; Cui X; Hilsenbeck SG; Lee AV
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of loss of heterozygosity of p53 gene in paraffin-embedded breast cancers by non-isotopic PCR-SSCP.
    Chen YH; Li CD; Yap EP; McGee JO
    J Pathol; 1995 Oct; 177(2):129-34. PubMed ID: 7490678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
    Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M
    Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients.
    Berns EM; Klijn JG; Smid M; van Staveren IL; Look MP; van Putten WL; Foekens JA
    Genes Chromosomes Cancer; 1996 Jul; 16(3):170-9. PubMed ID: 8814449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer.
    Roncuzzi L; Brognara I; Baiocchi D; Amadori D; Gasperi-Campani A
    Oncol Rep; 2005 Aug; 14(2):471-4. PubMed ID: 16012732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk.
    Han S; Lee KM; Choi JY; Park SK; Lee JY; Lee JE; Noh DY; Ahn SH; Han W; Kim DH; Hong YC; Ha E; Yoo KY; Kang D
    Breast Cancer Res Treat; 2008 Jul; 110(2):387-93. PubMed ID: 17940865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The expression of c-myb is strongly associated with the presence of estrogen and progesterone receptors in breast cancer].
    Guerin M; Barrois M; Riou G
    C R Acad Sci III; 1988; 307(20):855-61. PubMed ID: 2907731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors.
    Iwase H; Greenman JM; Barnes DM; Hodgson S; Bobrow L; Mathew CG
    Cancer Lett; 1996 Nov; 108(2):179-84. PubMed ID: 8973592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism.
    Hill SM; Fuqua SA; Chamness GC; Greene GL; McGuire WL
    Cancer Res; 1989 Jan; 49(1):145-8. PubMed ID: 2562795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer.
    Murphy LC; Hilsenbeck SG; Dotzlaw H; Fuqua SA
    Clin Cancer Res; 1995 Feb; 1(2):155-9. PubMed ID: 9815968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.